Dehydroepiandrosterone for systemic lupus erythematosus

Area of Science:

• Rheumatology
• Immunology
• Endocrinology

Background:

• Systemic lupus erythematosus (SLE) is a chronic, multisystem autoimmune disease.
• Dehydroepiandrosterone (DHEA), a naturally occurring steroid, is investigated for potential disease-modifying properties in SLE.
• DHEA may reduce SLE flares and decrease the need for steroid medications.

Purpose of the Study:

• To evaluate the efficacy and safety of dehydroepiandrosterone (DHEA) compared to placebo in treating patients with systemic lupus erythematosus (SLE).
• To assess DHEA's impact on disease activity, quality of life, and adverse events in SLE patients.

Main Methods:

• Systematic review and meta-analysis of randomized controlled trials (RCTs) of at least three months duration.
• Searches conducted across major databases including Cochrane Library, MEDLINE, PubMed, EMBASE, and Science Citation Index.
• Two independent reviewers assessed study quality and extracted data from seven identified RCTs involving 842 participants.

Main Results:

• Dehydroepiandrosterone (DHEA) demonstrated minimal clinical effect on disease activity (SLEDAI/SLAM) in mild/moderate SLE, though one study showed improvement in 8.3% more patients than placebo.
• A modest, clinically significant improvement in health-related quality of life was observed, estimated at 11.5% via meta-analysis.
• Increased adverse events were noted with DHEA, particularly androgenic effects like acne, doubling the risk compared to placebo (RR 2.2).

Conclusions:

• Dehydroepiandrosterone (DHEA) provides a modest short-term benefit for health-related quality of life in systemic lupus erythematosus (SLE) patients.
• Evidence for DHEA's impact on disease activity is inconsistent, with no significant benefit over placebo in most studies measuring SLEDAI.
• Long-term outcomes and safety profiles of DHEA in SLE remain uninvestigated.